Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol and Rosuvastatin in Peripheral Artery Disease
NCT07600385Phase 3Completed
- Sponsor
- Korea United Pharm Inc.
- Start
- Mar 2019
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cilostazol in Peripheral Arterial Disease (PAD) (2 arms), sponsored by Korea United Pharm Inc. Primary endpoint: Korean Peripheral Artery Questionnaire Summary Score at 24 weeks. Started Mar 2019; status: completed.
02
Drugs
cilostazol
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT07600385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07600385.